



Docket No. 157-47577-C

gp 1644  
J. H. Pyle  
#181/D

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: W. Marasco, et al.

RECEIVED

Serial No.: 09/522,727

Group No.: 1644

MAY 25 2001

Filed: March 10, 2000

Examiner Roark, J.

TECH CENTER 1600/29

For: INTRABODY-MEDIATED CONTROL OF IMMUNE REACTIONS


The Assistant Commissioner for Patents  
Washington, D.C. 20231


Sir:

Certificate of Mailing

I hereby certify that the following items are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to The Commissioner of Patents and Trademark, Washington, DC 20231, on this 21st day of May, 2001:

1. Submission of Sequence Listing (2 pp.);
2. Sequence Listing (14 pp.);
3. Diskette containing Sequence Listing
4. copy of Notice to Comply and Raw Sequence Listing Error Report; and
5. Transmittal of Substitute Specification Sheets (2 pp.);
6. Substitute Specification Sheets - pp. 44-60
7. Return Receipt Postcard.

  
Zinna L. Mang



Docket No. 157-47577-C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re application of: W. Marasco, et al.  
Serial No.: 09/522,727 Group No.: 1644 MAY 25 2001  
Filed: March 10, 2000 Examiner Roark, J.  
For: INTRABODY-MEDIATED CONTROL OF IMMUNE REACTION TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL OF SUBSTITUTE SPECIFICATION SHEETS (37 C.F.R. § 1.125)

NOTE: A substitute specification, excluding the claims, may be filed at any point up to payment of the issue fee if it is accompanied by items indicated below. See 37 C.F.R. § 1.125(b).

1. Enclosed are substitute specification sheets 44-60 for pages 44-46 of the originally filed specification in this application.

NOTE: The substitute specification must be submitted in clean form without markings as to amended material. 37 C.F.R. § 1.125(c).

2. (complete the following applicable item)

☒ [X] This substitute specification is submitted, in response to a requirement by the Examiner. Namely, filing of SEQUENCE LISTING.

OR

☐ [ ] This substitute specification is being voluntarily submitted, in order to facilitate the processing of


CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.10)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: 5/21/01

  
Signature

Zinna L. Mang  
(type or print name of person certifying)

the application.

3. As required by 37 C.F.R. § 1.125, the undersigned states that the substitute specification transmitted herewith contains no new matter.

RECEIVED

MAY 25 2001

  
SIGNATURE OF PRACTITIONER

TECH CENTER 1600/2900

Reg. No. 30,628

Ronald I. Eisenstein

(type or print name of practitioner)

Tel. No. (617) 345-6054

Nixon Peabody LLP


101 Federal Street

P.O. Address

Customer No.

Boston, Massachusetts 02110

# Notice to Comply



Application No.

09/522,727

Examiner

Jessica H. Roark

Applicant(s)

MARASCO ET AL.

Art Unit

1644

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

### Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**